LUND, Sweden, Feb. 16, 2018 /PRNewswire/ -- SenzaGen (Nasdaq First North: SENZA) announces today that the company has signed a global licensing agreement with the leading contract research organization Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD™ test to its clients. GARD™ is a genome-based test, with higher accuracy than other available test methods that gives the customers important safety information whether chemical substances are at risk of causing allergies in humans.
Eurofins BioPharma Product Testing is the largest network of harmonized bio/pharmaceutical GMP/GLP product testing laboratories worldwide with 30 facilities all over the world, providing comprehensive laboratory services for the world's major pharmaceutical, biopharmaceutical and medical device companies. The Munich subsidiary of Eurofins BioPharma Product Testing was part of the successful ring trial in the validation of GARDskin™, which was completed in the autumn of 2017.
Under the terms of the agreement, Eurofins BPT Munich will immediately include GARDskin™ and the add on test GARDpotency™ as a leading diagnostic tool in its chemical safety testing services to clients in the cosmetic, chemical and pharmaceutical industries worldwide.
"This new license agreement with such a major and strong partner provides an important stepping stone in the global marketing of GARD and it is also a hallmark of the high quality and relevance of GARD. We are very pleased to sign this important deal, in particular since Eurofins BPT Munich is a leading player in chemical safety testing, with a pronounced mission to contribute to global health and safety," says SenzaGen's CEO Anki Malmborg Hager.
GARDskin has the potential to meet the increasing demands in the cosmetics, chemicals and pharmaceutical industries for reliable, animal-free testing methods to assess the allergy-inducing properties of chemical substances. The test is in the process of obtaining regulatory approval and inclusion in international test guidelines.
For more information:
About Eurofins BioPharma Product Testing, Munich
Eurofins BPT Munich is part of the world's largest network of biopharmaceutical GMP/GLP testing laboratories. With more than 30 years of experience Eurofins BPT Munich provides a comprehensive testing portfolio to its clients in the fields of biopharma product testing, medical device testing and human safety testing.
Eurofins BPT Munich is a leader in in vitro and ex vivo safety testing. By offering its clients a comprehensive set of alternative in vitro and ex vivo test methods Eurofins BPT Munich provides the full service toxicological evaluation under GLP.
Eurofins BPT Munich offers clients the flexibility to choose from its fee-for-service, FTE, and the award-winning Professional Scientific Services® (PSS) service models in order to meet clients' specific project needs.
For more information please visit www.eurofins.com/human-safety-testing
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com
This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above on the 15 February, 2018 at 10:30.
SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company's Certified Adviser. For more information, please visit www.senzagen.com